Multivariate regression analyses on the potential associations of preoperative diffusion-weighted imaging grading on various pathologic outcomes.

<p>Multivariate regression analyses on the potential associations of preoperative diffusion-weighted imaging grading on various pathologic outcomes.</p

The concordance rates of index lesions between diffusion-weighted imaging and prostatectomy specimen and the incidences of high grade disease according to diffusion-weighted imaging grade.

<p>The concordance rates of index lesions between diffusion-weighted imaging and prostatectomy specimen and the incidences of high grade disease according to diffusion-weighted imaging grade.</p

The examples of diffusion weighted images according to the Likert score; (A) grade III; (B) grade IV; (C) grade V.

<p>The examples of diffusion weighted images according to the Likert score; (A) grade III; (B) grade IV; (C) grade V.</p

Clinicopathologic characteristics of subjects according to the suspicion level for prostate cancer determined from diffusion weighted imaging.

<p>Clinicopathologic characteristics of subjects according to the suspicion level for prostate cancer determined from diffusion weighted imaging.</p

Clinical Value of Core Length in Contemporary Multicore Prostate Biopsy

<div><p>Objectives</p><p>There is little data about the clinical value of core length for prostate biopsy (PBx). We investigated the clinical values of various clinicopathological biopsy-related parameters, including core length, in the contemporary multi-core PBx.</p><p>Patients and Methods</p><p>Medical records of 5,243 consecutive patients who received PBx at our institution were reviewed. Among them, 3,479 patients with prostate-specific antigen (PSA) ≤10ng/ml level who received transrectal ultrasound (TRUS)-guided multi (≥12)-core PBx at our institution were analyzed for prostate cancer (PCa). Gleason score upgrading (GSU) was analyzed in 339 patients who were diagnosed with low-risk PCa and received radical prostatectomy. Multivariate logistic regression analyses for PCa detection and prediction of GSU were performed.</p><p>Results</p><p>The mean age and PSA of the entire cohort were 63.5 years and 5.4ng/ml, respectively. The overall cancer detection rate was 28.5%. There was no statistical difference in core length between patients diagnosed with PCa and those without PCa (16.1 ± 1.8 vs 16.1 ± 1.9mm, <i>P</i> = 0.945). The core length was also not significantly different (16.4 ± 1.7 vs 16.4 ± 1.6mm, <i>P</i> = 0.889) between the GSU group and non-GSU group. Multivariate logistic regression analyses demonstrated that the core length of PBx did not affect PCa detection in TRUS-guided multi-core PBx (<i>P</i> = 0.923) and was not prognostic for GSU in patients with low-risk PCa (<i>P</i> = 0.356).</p><p>Conclusions</p><p>In patients undergoing contemporary multi-core PBx, core length may not have significant impact on PCa detection and also GSU following radical prostatectomy among low-risk PCa group.</p></div

Comparison of clinicopathological features among men who received contemporary multicore prostate biopsy and had PSA levels ≤ 10 ng/ml.

<p>Abbreviations: BMI, body mass index; PSA, prostate-specific antigen; DRE, digital rectal examination; TRUS, transrectal ultrasound</p><p>Data are presented as means ± standard deviations.</p><p>Comparison of clinicopathological features among men who received contemporary multicore prostate biopsy and had PSA levels ≤ 10 ng/ml.</p

Univariate and multivariate analyses of clinicopathological factors and detection of prostate cancer via prostate biopsy.

<p>Abbreviations: OR, odds ratio; CI, confidence interval; PSA, prostate-specific antigen;</p><p>DRE, digital rectal examination; TRUS, transrectal ultrasound</p><p>Univariate and multivariate analyses of clinicopathological factors and detection of prostate cancer via prostate biopsy.</p

Comparison of clinicopathological features among men diagnosed with low-risk prostate cancer according to Gleason score upgrading (GSU).

<p>Abbreviations: GSU, Gleason score upgrading; BMI, body mass index; PSA, prostate-specific antigen</p><p>Data are presented as means ± standard deviations.</p><p>Comparison of clinicopathological features among men diagnosed with low-risk prostate cancer according to Gleason score upgrading (GSU).</p